NF2患者大型前庭神经鞘瘤的当前管理:国家参考中心经验
该单中心回顾性队列研究纳入2016–2018年巴黎Pitié-Salpêtrière医院NF2国家参考中心54例Koos IV期前庭神经鞘瘤患者,分析手术、贝伐珠单抗和观察三种治疗方式的预后,并据此提出基于肿瘤进展、听力和临床状态及对侧VS大小的决策树。
要点
- Koos IV期VS在NF2中治疗选择多样,需个体化决策。
- 手术组1年面神经功能良好(HB I-II)达81.5%。
- 听力保留率:手术14%、贝伐珠单抗78%、观察66%。
核心结论
- 所有治疗选择包括手术和/或贝伐珠单抗及偶尔观察,应在专科中心背景下提供给NF2大型VS患者。
- 基于肿瘤演变、听力和临床状态及对侧VS大小,提出了Koos IV期VS管理的决策树。
研究设计与样本
- 回顾临床病历、影像学、手术报告和听力图。
主要发现
- 54例NF2患者中,27例手术(28个VS),21例接受贝伐珠单抗治疗,6例观察。
- 手术组肿瘤切除程度:全切除32%、近全切除25%、次全切除32%、部分切除11%。
- 手术组1年面神经功能良好(House-Brackmann I-II级)达81.5%。
- 听力保留率:手术组14%(n=7)、贝伐珠单抗组78%(n=9)、观察组66%(n=3)。
临床怎么用
- NF2患者大型VS应在专科中心评估,综合手术、贝伐珠单抗和观察等选项。
- 决策需考虑肿瘤演变、听力及临床状态和对侧VS大小。
局限性
- 证据等级为4级,属病例系列研究及历史对照研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Recently, treatment decision making for large vestibular schwannomas (VS) in patients with neurofibromatosis type 2 (NF2) has become increasingly challenging due to the availability of multiple therapeutic options including surgery, bevacizumab (an anti-VEGF), radiosurgery, and observation; and it often remains an arbitrary decision based on local practices without firm recommendations. Our objective is to discuss the multimodal treatment options for Koos IV VS in a national reference center for NF2. STUDY DESIGN: Single-institution retrospective cohort study. METHODS: All NF2 patients with Koos IV VS who visited our center, the National Reference Center for NF2 Rare Disease in Pitié-Salpétrière Hospital of Paris, between January 2016 and December 2018 were included. Clinical charts, radiology, operative reports, and audiograms were reviewed. RESULTS: Among 54 NF2 patients with Koos IV VS (mean maximum extrameatal diameter: 34 mm; range:17-62 mm), 27 were operated on for 28 VS; 21 were treated with bevacizumab; and six were observed. In the surgical group, VS resections were gross total, near-total, subtotal, or partial in 32%, 25%, 32%, and 11%, respectively; and a good (House-Brackmann grades I-II) facial nerve function was achieved in 81.5% at 1 year. Hearing was preserved in 14%, 78%, and 66% of the surgical (n = 7), bevacizumab (n = 9), and observation (n = 3) patients, respectively. CONCLUSION: All therapeutic options, including surgery and/or bevacizumab and occasionally observation, should be proposed to NF2 patients with large VS in the setting of dedicated centers. A decision-making tree is proposed for Koos IV VS management based on tumor evolution, hearing and clinical status of the patient, and contralateral VS size. LEVEL OF EVIDENCE: 4, case series study, historically controlled study Laryngoscope, 131:E98-E107, 2021.
引用
- Comes PC, Peyre M, Sanson M, et al. Current Management of Large Vestibular Schwannomas for NF2 Patients in a National Reference Center. Laryngoscope. 2020. PMID: 33270257. doi:10.1002/lary.28998
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。